AM-112
AM-112 is a β-lactamase (β-lactamase) inhibitor and antibacterial agent, with IC50 values ranging from 0.0002 μg/mL to 0.67 μg/mL against class A, C, and D β-lactamase. By inhibiting PBP2, the penicillin-binding protein of E. coli, and protecting Ceftazidime (HY-B0593) from enzymatic hydrolysis, AM-112 significantly enhances the antibacterial efficacy of Ceftazidime against Gram-negative bacteria, enterococci, and staphylococci. AM-112 exhibits favorable pharmacokinetic properties and acid-base stability. AM-112 can be used for the research of bacterial infections.
For research use only. We do not sell to patients.
- CAS No.: 414858-51-8
- Formula: C14H22N2O5
- Molecular Weight:298.34
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
|
β-lactam |
In Vitro
AM-112 (combined with Ceftazidime at a 2:1 ratio) synergistically reduces the MIC of Ceftazidime (HY-B0593) in all tested Enterococcus faecalis strains, with the greatest MIC reduction observed in E. faecalis SFZ (from 64 μg/mL to 8 μg/mL)[1].
AM-112 (0.5-32 μg/ml; 18-24 h) has an MIC of 2 μg/mL against Methicillin (HY-121544)-susceptible Staphylococcus aureus, an MIC range of 4-16 μg/mL against anaerobic bacteria of the genera Clostridium and Bacteroides, and an MIC of ≥32 μg/mL against Escherichia coli, Pseudomonas, Acinetobacter, Enterococcus and Methicillin-resistant Staphylococcus aureus[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Multiple bacterial strains including Escherichia coli, Enterobacter cloacae, Enterococcus faecalis, Pseudomonas aeruginosa ATCC 27853 producing Class A or Class C β-lactamases
-
Concentration:10 μg of AM-112 per disk, combined with 30 μg Ceftazidime per disk
-
Incubation Time:overnight incubation at 37℃
-
Result:Enhanced the zone diameter of Ceftazidime against bacterial isolates producing Class A and Class C β-lactamases, while it showed no enhancing effect on the activity of Ceftazidime against Pseudomonas aeruginosa ATCC 27853.
Parmacokinetics
In Vivo
AM-112 (administered intravenously at 1.9-19 mg/kg) exhibits inhibitory effects against E. cloacae P99-induced sepsis in mice, with an ED50 of 19 mg/kg, and significantly enhances the efficacy of Ceftazidime when co-administered[1].
AM-112 (>40 mg/kg; s.c.) shows limited inhibitory effect on K. pneumoniae SHV-5-induced sepsis in mice, with an ED50 >40 mg/kg, but it can enhance the efficacy of Ceftazidime when administered in combination[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:ICR mice (male, 20-22 g, intraperitoneal inoculation with S. aureus 3816)[1]
-
Dosage:2.6 mg/kg (alone); 1.2 mg/kg (4:1 CAZ:AM-112 combination); 1 mg/kg (7:1 CAZ:AM-112 combination)
-
Administration:subcutaneous injection
-
Result:Had an ED50 of 2.6 mg/kg (95% CI: 2.2-3.1 mg/kg).
Had an ED50 of 1.2 mg/kg (95% CI for co-administered ceftazidime: 4.0-5.8 mg/kg) in 4:1 CAZ:AM-112 combination.
Had an ED50 of 1 mg/kg (95% CI for co-administered ceftazidime: 6.6-9.7 mg/kg) in 7:1 CAZ:AM-112 combination.
-
Animal Model:CD1 mice (male, 20-22 g, intraperitoneal inoculation with E. cloacae P99)[1]
-
Dosage:19 mg/kg (alone); 2 mg/kg (1:1 CAZ:AM-112 combination); 1.9 mg/kg (2:1 CAZ:AM-112 combination); 2.9 mg/kg (4:1 CAZ:AM-112 combination)
-
Administration:intravenous injection
-
Result:Had an ED50 of 19 mg/kg (95% CI: 11.6-33.4 mg/kg).
Had an ED50 of 2 mg/kg (95% CI for co-administered ceftazidime: 1.0-5.5 mg/kg) in 1:1 CAZ:AM-112 combination.
Had an ED50 of 1.9 mg/kg (95% CI for co-administered ceftazidime: 2.3-5.9 mg/kg) in 2:1 CAZ:AM-112 combination.
Had an ED50 of 2.9 mg/kg (95% CI for co-administered ceftazidime: 7.2-17.4 mg/kg) in 4:1 CAZ:AM-112 combination.
-
Animal Model:ICR mice (female, 20-22 g, intraperitoneal inoculation with K. pneumoniae SHV-5)[1]
-
Dosage:>40 mg/kg (alone); 33.6 mg/kg (1:1 CAZ:AM-112 combination); 11.9 mg/kg (2:1 CAZ:AM-112 combination)
-
Administration:subcutaneous injection
-
Result:Had an ED50 of >40 mg/kg (no 95% CI determined).
Had an ED50 of 33.6 mg/kg (95% CI for co-administered ceftazidime: 25.1-45.1 mg/kg) in 1:1 CAZ:AM-112 combination.
Had an ED50 of 11.9 mg/kg (95% CI for co-administered ceftazidime: 18.8-30.1 mg/kg) in 2:1 CAZ:AM-112 combination.
Chemical Information
-
CAS No. 414858-51-8
-
Molecular Weight 298.34
-
Formula C14H22N2O5
-
SMILES
[C@H](C)(O)[C@@]1([C@@]2(N(C(C(O)=O)=C(C(CCCN)(C)C)O2)C1=O)[H])[H]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Gram Staining of Tissue Sections
Gram staining of tissue sections is a histochemical technique used to differentiate Gram-positive and Gram-negative bacteria within histological specimens based on differences in bacterial cell wall structure and dye retention, adapted from classical bacteriological Gram staining into tissue-compatible “histological Gram stain” variants. In tissue applications, modifications of the Brown-Hopps and Brown-Brenn methods are commonly used to improve differentiation of microorganisms embedded within host connective tissue and to reduce overstaining or loss of Gram-negative signal, which are known limitations of earlier approaches. The principle relies on crystal violet-iodine complex retention in Gram-positive organisms and subsequent decolorization and counterstaining steps that allow contrast visualization of Gram-negative organisms against tissue background.
Purity & Documentation
References
[1]. Simpson IN, et al. Synthesis and biological activity of AM-112 and related oxapenem analogues. J Antibiot (Tokyo). 2003;56(10):838-847. [Content Brief]
[2]. Jamieson CE, et al. In vitro activities of novel oxapenems, alone and in combination with ceftazidime, against gram-positive and gram-negative organisms. Antimicrob Agents Chemother. 2003;47(8):2615-2618. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- AM-112
- 414858-51-8
- AM112
- AM 112
- Antibiotic
- Beta-lactamase
- Bacterial
- Penicillin-binding protein (PBP)
- Class D β-lactamases
- β-lactamase inhibitor
- Class C β-lactamases
- Class A β-lactamases
- Escherichia coli
- Staphylococcus aureus
- penicillin-binding protein 2
- bacterial infection
- Enterococcus faecalis
- Gram-negative bacteria
- Inhibitor
- inhibitor
- inhibit